Detalhe da pesquisa
1.
Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
J Neurooncol
; 154(3): 353-364, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34498213
2.
Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors.
JCO Glob Oncol
; 10: e2300011, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38237094
3.
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Target Oncol
; 18(3): 425-440, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37017806
4.
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.
Ther Adv Respir Dis
; 16: 17534666211066064, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35098800
5.
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP).
Front Oncol
; 12: 904800, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35903685
6.
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Clin Lung Cancer
; 23(6): 522-531, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35798634
7.
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Lung Cancer
; 170: 114-121, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35753125